Rumors about the astonishing weight loss potential of Eli Lilly's triple hormone drug retatrutide have been circulating for months. The results of its Phase 3 clinical trial, just released by the ...

As Eli Lilly looks to hold its lead in the lucrative obesity market, the company’s next-gen prospect, the triple-G drug retatrutide, has met the primary endpoint for weight loss in another pivotal ...

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

“How do they do that?” is a reasonable response to certain things we see in nature. Pythons and snakes like them can eat prey as big as they are, sometimes even bigger, and digest their massive single ...

At the NAB Show in Las Vegas last month, Pearl TV, the consortium of broadcasters, manufacturers and industry advocates showcased prototypes of new converter boxes that would allow consumers to ...

WeightWatchers' Core+ program offers personalized weight loss support starting at $20 per month. The program focuses on nutrition, habit-building and community support. Core+ features specialized ...

MEMPHIS, Tenn. — April is National Second Chance Month. In its honor, FOX13 is highlighting B.R.I.D.G.E. (Building Renewed Independence. Dignity, Growth, and Empowerment). It's a year-round program ...

Medicare has delayed a program for older Americans that would've required participating insurance companies to cover GLP-1 weight loss drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound.

Demand for weight loss drugs is ballooning across the U.S. — and Amazon wants in. The Seattle-based tech giant launched its own GLP-1 program Tuesday aimed at streamlining access to weight loss drugs, ...